Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Sulodexide is a mixed glycosaminoglycan composed of heparinand dermatan sulfate. In this study, the anti-angiogeniceffect of sulodexide was investigated using an oxygen-inducedretinopathy (OIR) mouse model. The retinas of sham-injectedOIR mice (P17) had a distinctive central area of nonperfusion,and this area was significantly decreased in sulodexide-injectedmice. The number of neovascular tufts measured bySWIFT_NV and mean neovascular lumen number were significantlydecreased in sulodexide-injected mice. Hyperbaricoxygen exposure resulted in increased levels of VEGF, MMP-2and MMP-9, and when mice were treated with sulodexide, adose-dependent reduction in VEGF, MMP-2 and MMP-9 levelswas observed. Our results clearly demonstrate the anti-angiogeniceffect of sulodexide and highlight sulodexide as acandidate supplementary substance to be used for the treatmentof ocular pathologies that involve neovascularization.
Abstract
Sulodexide is a mixed glycosaminoglycan composed of heparinand dermatan sulfate. In this study, the anti-angiogeniceffect of sulodexide was investigated using an oxygen-inducedretinopathy (OIR) mouse model. The retinas of sham-injectedOIR mice (P17) had a distinctive central area of nonperfusion,and this area was significantly decreased in sulodexide-injectedmice. The number of neovascular tufts measured bySWIFT_NV and mean neovascular lumen number were significantlydecreased in sulodexide-injected mice. Hyperbaricoxygen exposure resulted in increased levels of VEGF, MMP-2and MMP-9, and when mice were treated with sulodexide, adose-dependent reduction in VEGF, MMP-2 and MMP-9 levelswas observed. Our results clearly demonstrate the anti-angiogeniceffect of sulodexide and highlight sulodexide as acandidate supplementary substance to be used for the treatmentof ocular pathologies that involve neovascularization.
참고문헌 (26)
- Aiello, L. P., "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins", Proc. Natl. Acad. Sci. U. S. A, 92, pp.10457~10461 (1995)
- Kim, J,, "Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity", Retina, 34, pp.77~82 (2014)
- Simpson, J. L., "Current role of cryotherapy in retinopathy of prematurity: a report by the American Academy of Ophthalmology", Ophthalmology, 119, pp.873~877 (2012)
- Condorelli, M., "IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction", J. Am. Coll. Cardiol, 23, pp.27~34 (1994)
- Lasierra-Cirujeda, J., "Use of sulodexide in patients with peripheral vascular disease", J. Blood Med, 1, pp.105~115 (2010)
- Kristova, V., "Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats", Physiol. Res, 57, pp.491~494 (2008)
- Corbu, C., "Sulodexide treatment in retinal vein obstructions", Oftalmologia, 40, pp.393~397 (1996)
- Weiss, R., "The role of sulodexide in the treatment of diabetic nephropathy", Drugs, 67, pp.2681~2696 (2007)
- Harenberg, J., "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide", Med. Res. Rev, 18, pp.1~20 (1998)
- Lauver, D. A., "Sulodexide: a renewed interest in this glycosaminoglycan", Cardiovasc. Drug Rev, 24, pp.214~226 (2006)
- Pletinck, A., "Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion", Nephrol. Dial. Transplant, 27, pp.548~556 (2012)
- Simonetti, O., "Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions", Cancer, 95, pp.1963~1970 (2002)
- Hollborn, M., "Positive feedback regulation between MMP-9 and VEGF in human RPE cells", Invest. Ophthalmol. Vis. Sci, 48, pp.4360~4367 (2007)
- Oshima, Y., "Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization", J. Cell Physiol, 201, pp.393~400 (2004)
- Yafai, Y., "Retinal endothelial angiogenic activity: effects of hypoxia and glial (Muller) cells", Microcirculation, 11, pp.577~586 (2004)
- Pennock, S., "Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses", Mol. Cell Biol, 32, pp.1955~1966 (2012)
- DeNiro, M., "Inhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy", PLoS One, 6, pp.e22244~ (2011)
- Gambaro, G., "Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial", J. Am. Soc. Nephrol, 13, pp.1615~1625 (2002)
- Broekhuizen, L. N., "Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus", Diabetologia, 53, pp.2646~2655 (2010)
- Packham, D. K., "Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy", J. Am. Soc. Nephrol, 23, pp.123~130 (2012)
- Watanabe, D., "Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy", Am. J. Ophthalmol, 139, pp.476~481 (2005)
- Kim, N. H., "Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy", Kidney Int, 67, pp.167~177 (2005)
- Smith, L. E., "Oxygen-induced retinopathy in the mouse", Invest. Ophthalmol. Vis. Sci, 35, pp.101~111 (1994)
- Li, S., "Retro-orbital injection of FITC-dextran is an effective and economical method for observing mouse retinal vessels", Mol. Vis, 17, pp.3566~3573 (2011)
- Nanni, C., "Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies", Nucl. Med. Commun, 28, pp.547~553 (2007)
- Connor, K. M., "Quantification of oxygen- induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis", Nat. Protoc, 4, pp.1565~1573 (2009)